Drug intelligence / Profile preview

tipepidine hibenzate

Development stage
Phase 2
Modality
Small Molecules
Administration
Oral
01

Overview

Tipepidine hibenzate is a synthetic, non-opioid antitussive and expectorant of the thiambutene class. Developed in Japan in 1959, it is primarily used to suppress cough and facilitate sputum discharge, especially for symptoms associated with cold and bronchitis. Its mechanism of action involves inhibition of G protein-coupled inwardly rectifying potassium channels (GIRK), which modulates monoaminergic neurotransmission in the brain. This action not only underlies its antitussive effect but also leads to increased dopamine levels in the nucleus accumbens, contributing to potential antidepressant-like effects. Tipepidine has been investigated for use beyond cough suppression, including attention-deficit hyperactivity disorder (ADHD), depression, and obsessive-compulsive disorder[2][3][5]. It is administered orally and has an established safety profile in both children and adults.

Brand names
AsverinAntupexAsvelikAsvexBitiodinCofdenin AHustelNodalSotal
Other names
tipepidine hibenzatetipepidine ibenzatotipepidine citrate (1:1)Asverin H
02

Targets

GIRK (G protein-coupled inward-rectifier potassium channel)

Beyond the preview

Go deeper on tipepidine hibenzate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on tipepidine hibenzate.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call